Keywords: American College of Cardiology; American Heart Association; Arterial Revascularization Trial; CardiAQ; Cox lesion set; HeartMate 3; HeartMate II; HeartWare; INTERMACS; Intrepid; MITRAL; MOMENTUM 3; Seattle Heart Failure, Model; Society of Thoracic Surgeons; Tendyne; Tiara; aortic stenosis; atrial fibrillation; axial flow; balloon-inflatable prosthesis; beta blocker; bicuspid aortic valve; bioresorbable stent; bleeding; cardiopulmonary bypass; centrifugal flow; coronary artery bypass grafting; drug-eluting stent; dual antiplatelet therapy; functional capacity; heart failure, levosimendan, left ventricular assist device; heart transplantation; internal mammary graft; left atrial appendage; left atrium; mitral regurgitation; mortality; myocardial infarction; noncardiac surgery; off-pump; on-pump; paravalvular leak; percutaneous coronary intervention; perioperative risk of mortality score; pulmonary vein isolation; quality of life; saphenous vein graft; seizures; self-inflating prosthesis; stroke; surgical ablation; surgical aortic valve replacement; surgical risk; tranexamic acid; transcatheter aortic valve replacement; transfusion; valve-in-ring replacement; valve-in-valve replacement.